drugset / Trial / NCT03333187
Ruxolitinib vs Allogeneic SCT for Patients With Myelofibrosis According to Donor Availability
Phase 2
Active not recruiting
87 enrolled
University Medical Center Hamburg-Eppendorf
Clinical Trial Center North (CTC North GmbH & Co. KG) · collabNovartis · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The present study will be a multicenter, prospective phase II-study comparing efficacy of allogeneic SCT for patients with myelofibrosis who have a suitable stem cell donor after a 3 months Ruxolitinib induction therapy with patients who lack a suitable stem cell donor and will continue to receive Ruxolitinib.
Timeline
- Start
- 2016-12-21
- Primary completion
- 2024-10-07
- Completion
- 2025-10-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ruxolitinib | Small molecule | — | — |